



IGRT for SBRT and particle therapy

Matthias Guckenberger, MD


Outline

- 1. Rational for IGRT**
- 2. Technologies for IGRT**
- 3. Pitfalls and challenges in IGRT**
- 4. Clinical evidence for IGRT**

Outline

- 1. Rational for IGRT**
2. Technologies for IGRT
3. Pitfalls and challenges in IGRT
4. Clinical evidence for IGRT


Traditional patient set-up: skin marks




Constant relationship between skin marks and internal anatomy ?

Inter-fractional base line shifts in lung SBRT


Patient positioning



Bone set-up




Tumor set-up




Base-line shifts independently from the bony anatomy

Inter-fractional base line shifts in lung SBRT



Mean: 5.3mm **90th**
percentile: 8mm

Guckenberger et al. 2006




Mean: 6.8mm **90th**
percentile: 13.9mm

Prudie et al. 2007

Dosimetric effects in “Photon” SBRT

Galerani IJROBP 2010



Dosimetric effects in lung SBRT

- ITV concept
- 5mm PTV margin


No IGRT

- Minimum CTV dose
 - 6% on average
 - 50% on maximum

IGRT

- No relevant dose loss

Dosimetric effects in “Proton” SBRT



Increased complexity in Proton SBRT to compensate

- Tumor volume / shape changes
- Breathing motion

Outline

1. Rational for IGRT
- 2. Technologies for IGRT**
3. Pitfalls and challenges in IGRT
4. Clinical evidence for IGRT


Technologies for in-room IGRT

3D volume imaging

In-room CT



Cone-beam CT



MV CT



2D kV stereoscopic imaging



2D & 3D imaging






Image quality of in-room CT imaging


Helical




kV CBCT



MV CT




**kV/MV
CBCT**




- Intra-pulmonary targets clearly visible in all imaging modalities
- IQ for mediastinum suitable only in kV helical CT

Integration of 4th dimension into IGRT

Planning



**Respiration
correlated CT**




Treatment



**Respiration
correlated CBCT**

Where 4D CB-CT improves accuracy



**Mobile tumors located
immediatly superior
the diaphragm**

2D IGRT – implanted markers




Image from
www.Brainlab.com

- Markers required: poor soft-tissue contrast
- Surrogate, not the target itself

2D IGRT – implanted markers

	Type of markers	Implantation method	Success rate
<i>de May 2005</i>	Coils	Transthoracic	100%
<i>Kupelian 2007</i>	Coils	Transthoracic Transbronchial	100% 100%
<i>Bgagat 2010</i>	Seeds	Transthoracic	81%
<i>Hong 2011</i>	Coils Seeds	Transthoracic	99.3% 85.3%

2D IGRT – implanted markers

	Type of markers	Implantation method	Success rate
<i>de May 2005</i>	Coils	Transthoracic	100%
<i>Kupelian 2007</i>	Coils	Transthoracic Transbronchial	100% 100%
<i>Bgagat 2010</i>	Seeds	Transthoracic	81%
<i>Hong 2011</i>	Coils Seeds	Transthoracic	99.3% 85.3%

- Seeds: high marker migration rate



2D IGRT – implanted markers

	Type of markers	Implantation method	Success rate	Pneumothorax	Chest tube
<i>de May 2005</i>	Coils	Transthoracic	100%		1/10
<i>Kupelian 2007</i>	Coils	Transthoracic Transbronchial	100% 100%	8/15 0/8	6/15 0/8
<i>Bgagat 2010</i>	Seeds	Transthoracic	81%	18/28	6/28
<i>Hong 2011</i>	Coils Seeds	Transthoracic	99.3% 85.3%	23% 54%	3% 29%

- Seeds: high marker migration rate
- Transthoracic approach: high rates of pneumothorax
- Transbronchial implantation of Coils


2D kV IGRT – markerless tracking

Bahig IJROBP 2013



2D kV IGRT – markerless tracking

Target diameter



“We recommend considering tumor tracking in all patients with tumors >3.5 cm based on >80% chance of adequate tumor visualization in this subgroup”

- Strategy in remaining 20% ?
- 95% success rate requires tumor diameter >5cm


Predictors for successful markerless tracking

- Tumor size
- Volume
- Density



2D MV IGRT – markerless tracking

EPID for target monitoring during SBRT

Richter IJROBP 2010



Volume
effect



Pros:

- Passive monitoring w/o additional irradiation dose or additional hardware

Cons:



- Successful in < 50% of SBRT cases
- Requires 3D-CRT

Outline



1. Rational for IGRT
2. Technologies for IGRT
- 3. Pitfalls and challenges in IGRT**
4. Clinical evidence for IGRT

Non-rigid uncertainties in NSCLC

Treatment planning




IGRT treatment



Dosimetric effects of base line shifts: ORGANS AT RISK





Galerani IJROBP 2010



Dose variability

1 SD	No-IGRT
Cord	14.1%
Esophagus	6.5%
PBT	17.5%
Aorta	19.5%

Clinical relevance of differential motion



Outline

1. Rational for IGRT
2. Technologies for IGRT
3. Pitfalls and challenges in IGRT
- 4. Clinical evidence for IGRT**

(Missing) Evidence in lung SBRT

Patterns of care and outcome in Germany and Austria:
n=582




IGRT

SBF



IGRT outside




IGRT inside


1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

(Missing) Evidence in lung SBRT

Patterns of care and outcome in Germany and Austria



(Missing) Evidence in lung SBRT



Rapid adoption of SBRT at least partially result of IGRT:

- Confidence in high-dose per fraction radiotherapy
- Improved and streamlined work-flow

CONCLUSIONS

- Image guidance broadly available on all modern linacs
 - Major **benefit** of volumetric IGRT: 3D and 4D visualization of target and OARs
 - Major **disadvantage** of volumetric IGRT: slow and limited usability for intra-fraction monitoring
 - Both 2D and 3D imaging suitable for lung SBRT
 - Integration of 4D breathing motion is essential
- Image guidance a mandatory QA procedure in SBRT